Mexico SGLT2 Inhibitor Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. SGLT2 Inhibitor market is growing globally due to the rising prevalence of type 2 diabetes, Efficacy and Safety Profile of these drugs is good in treating type 2 diabetes, promoting weight loss and protecting from cardiovascular diseases, expanded indications of these drugs to include management of heart failure with reduced ejection fraction and chronic kidney disease, advancements in drug development. Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals and Astellas are the key market players operating globally.
Mexico SGLT2 Inhibitor Market is valued at around $148.1 Mn in 2022 and is projected to reach $295.8 Mn by 2030, exhibiting a CAGR of 9.03% during the forecast period 2023-2030.
SGLT2 inhibitors are a class of drugs used in the treatment of type 2 diabetes. They work by blocking the action of SGLT2, a protein that helps move glucose from the bloodstream into the cells. By blocking SGLT2, these drugs reduce the amount of sugar absorbed by the body. Various drugs that come under SGLT2 Inhibitors are Dapagliflozin, Canagliflozin, and Empagliflozin. The dapagliflozin segment is expected to account for the largest share of the global SGLT2 inhibitor market and is also projected to grow the highest. Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals and Astellas are the key market players operating globally.
Market Growth Drivers
Increasing prevalence of type 2 diabetes, rising awareness about SGLT2 inhibitors, launch of new products, Efficacy and Safety Profile of these drugs is good in treating type 2 diabetes, promoting weight loss and protecting from cardiovascular diseases, expanded indications of these drugs to include management of heart failure with reduced ejection fraction and chronic kidney disease, advancements in drug development.
Market Restraints
Regulatory Challenges as obtaining regulatory approvals from health authorities for new indications or specific patient populations can be time-consuming and costly.
Competition from Other Diabetes Treatments: The SGLT2 inhibitor market faces competition from other classes of drugs used in the management of type 2 diabetes, such as metformin, sulfonylureas, DPP-4 inhibitors, and GLP-1 receptor agonists.
Pricing and Reimbursement issues
Key Players
In April 2022, the PMDA in Japan updated the label on the SGLT-2 inhibitor Jardiance (empagliflozin), allowing it to be used not only by people with heart failure with reduced ejection fraction (HFrEF) but also by people with chronic heart failure with preserved ejection fraction (HFpEF).
In February 2021, to lower the risk of cardiovascular (CV) death and hospitalization for heart failure (HF) in individuals with heart failure (NYHA classes II-IV with reduced ejection fraction (HFrEF), Forxiga (dapagliflozin), manufactured by AstraZeneca, was approved in China
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type
By Application
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.